High-dose etoposide: From phase I to a component of curative therapy

Journal of Clinical Oncology

Volumn 26, Issue 33, 2008, Pages 5310-5312

  Wolff, Steven N ^a   Hainsworth, John D ^b   Greco, F Anthony ^b  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE;

AREA UNDER THE CURVE; AUTOTRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; LEUKEMIA; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NOTE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETOPOSIDE; HUMANS; NEOPLASMS;

EID: 56749177279     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.0892     Document Type: Note

References (37)

1. Wolff SN, Fer MF, McKay CM, et al: High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: A phase I study. J Clin Oncol 1:701-705, 1983
2. Phillips GL, Fay JW, Herzig GP, et al: Intensive 1,3-bis(2-chloroethyl)- 1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer A phase I-II study. Cancer 52:1792-1802, 1983
3. Phillips GL, Wolff SN, Fay JW, et al: Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncol 4:639-645, 1986
4. Lazarus HM, Herzig RH, Graham-Pole J, et al: Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1:359-367, 1983
5. Lazarus HM, Phillips GL, Herzig RH, et al: High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol 26:2240-2243, 2008
6. Lazarus HM, Gottfried MR, Herzig RH, et al: Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer 49:1789-1795, 1982
7. Wolff SN, Herzig RH, Fay JW, et al: High-dose N,N′,N′- triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies. Semin Oncol 17:2-6, 1990
8. Shea TC, Flaherty M, Elias A, et al: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7:651-661, 1989
9. Appelbaum FR: Hematopoietic-cell transplantation at 50. N Engl J Med 357:1472-1475, 2007
10. Phillips GL, Herzig RH, Lazarus HM, et al: Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med 310:1557-1561, 1984
11. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
12. Brunvand MW, Bensinger WI, Soll E, et al: High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: Comparison of autologous bone marrow and peripheral blood stem cells. Bone Marrow Transplant 18:131-141, 1996
13. Bensinger WI, Martin PJ, Storer B, et al: Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175-181, 2001
14. Hofmeister CC, Stiff PJ: Mucosal protection by cytokines. Curr Hematol Rep 4:446-453, 2005
15. Brown RA, Herzig RH, Wolff SN, et al: High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76:473-479, 1990
16. Hande KR, Wedlund PJ, Noone RM, et al: Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44:379-382, 1984
17. Brown RA, Wolff SN, Fay JW, et al: High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: A study by the North American Marrow Transplant Group. Blood 85:1391-1395, 1995
18. Fleming DR, Wolff SN, Fay JW, et al: Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: A phase II study from the North American Marrow Transplant Group. Leuk Lymphoma 35:91-98, 1999
19. Phillips GL, Wolff SN, Herzig RH, et al: Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73:2086-2092, 1989
20. Horning SJ, Chao NJ, Negrin RS, et al: The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: Preliminary data. Ann Oncol 2:47-50, 1991 (suppl 1)
21. Horning SJ, Negrin RS, Chao JC, et al: Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12:2552-2558, 1994
22. Long GD, Chao NJ, Hu WW, et al: High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. Cancer 78:2502-2509, 1996
23. Weaver CH, Appelbaum FR, Petersen FB, et al: High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 11:1329-1335, 1993
24. Weaver CH, Petersen FB, Appelbaum FR, et al: High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 12:2559-2566, 1994
25. Wolff SN: High-dose carmustine and high-dose etoposide: A treatment regimen resulting in enhanced hepatic toxicity. Cancer Treat Rep 70:1464-1465, 1986
26. Stein RS, Greer JP, Goodman S, et al: Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma. Bone Marrow Transplant 25:257-262, 2000
27. Stein RS, Greer JP, Goodman S, et al: Is total body irradiation a necessary component of preparative therapy for autologous transplantation in non-Hodgkin's lymphoma. Leuk Lymphoma 41:97-103, 2001
28. Baron F, Storb R: Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol Ther 13:26-41, 2006
29. Giannone L, Wolff SN: Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation. Cancer Treat Rep 71:759-761, 1987
30. Greco FA, Johnson DH, Hande KR, et al: High-dose etoposide (VP-16) in small-cell lung cancer. Semin Oncol 12:42-44, 1985
31. Wolff SN, Birch R, Sarma P, et al: Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: A Southeastern Cancer Study Group Trial. Cancer Treat Rep 70:583-587, 1986
32. Wolff SN, Johnson DH, Hainsworth JD, et al: High-dose VP-16-213 monotherapy for refractory germinal malignancies: A phase II study. J Clin Oncol 2:271-274, 1984
33. Wolff SN, Johnson DH, Hande KR, et al: High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 67:957-958, 1983
34. Crump M, Gluck S, Tu D, et al: Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 26:37-43, 2008
35. Möbus V, Wandt H, Frickhofen N, et al: Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 25:4187-4193, 2007
36. Einhorn LH, Williams SD, Chamness A, et al: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340-348, 2007
37. Reya T, Morrison SJ, Clarke MF, et al: Stem cells, cancer, and cancer stem cells. Nature 414:105-111, 2001